PharmAla signs a supply and data deal for cGMP MDMA in a US open-label Phase 2 trial targeting PTSD in first responders

MDMA-assisted therapy gets a new clinical-investment angle as PharmAla Biotech signs a supply-and-data agreement for cGMP MDMA (LaNeo) in a U.S. open-label Phase 2 trial for post-traumatic stress in frontline healthcare workers and first responders. The deal pairs drug supply with data rights: PharmAla receives a perpetual, non-exclusive license to pseudonymized raw datasets plus safety and efficacy analyses for global regulatory and commercial use. PharmAla also completed shipment of MDMA to University College London for a previously announced academic study. The strategy is described as a “supply-for-data” model to build a diversified evidence base while keeping cash burn lower than traditional full-scale pivotal sponsorship. The piece also highlights regulatory skepticism around open-label MDMA datasets and therapist variability, while noting the operational benefits of consistent cGMP supply for dosing-day infrastructure, training, monitoring, and governance of consent and data-sharing across investigator-led work.